Search
forLearn
5 / 801 resultslearn PTD-DBM
learn catalase
learn acetyl tetrapeptide-3
learn PTT-6®
Research
5 / 1000+ resultsresearch Diphenyl cresyl phosphate [MAK Value Documentations, 2003]
Diphenyl cresyl phosphate has low toxicity but can harm the liver, kidneys, adrenal glands, and testicles at high doses.
research Mutamba fruits (Guazuma ulmifolia Lam.) - physical, physicochemical and antioxidant characterization
Mutamba fruits are rich in soluble solids, vitamin C, and minerals, making them good for food industry use.
research Prostaglandin-Induced Hair Growth
Latanoprost can make eyelashes longer, thicker, and darker.
research CD34 glycoprotein identifies putative stem cells located in the isthmic region of canine hair follicles
CD34 marks potential stem cells in dog hair follicles.
research Association of DNA damage with vitamin D and hair heavy metals of obese women
Adequate vitamin D might lower, and high hair chromium might increase DNA damage in obese women.
Community Join
5 / 1000+ results
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.